Oncolytics Biotech Inc.

Oncolytics Biotech Inc.

Oncolytics Biotech Inc.

Overview
Date Founded

1998

Headquarters

1167 Kensington Crescent NW,Suite 210,Calgary, AB T2N 1X7

Type of Company

Public

Employees (Worldwide)

25

Industries

Biotechnology
Medical Support Services
Hospitals & Patient Services
Pharmaceuticals

Company Description

Oncolytics Biotech, Inc. engages in the development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. It offers a non-pathogenic, properietary isolate of the reovirus that induce selective tumor lysis, and promotes an inflamed tumor phenotype through innate and adaptive immune responses. The company was founded by Matthew C. Coffey and Bradley George Thompson on April 2, 1998 and is headquartered in Calgary, Canada.

Contact Data
Trying to get in touch with decision makers at Oncolytics Biotech Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Co-Founder

Chief Financial Officer

Global Head of Business Development, President, Oncolytics BioTech (US) Inc

Vice President, Investor Relations & Corporate Communications

Vice President, Product Development

Global Head of Clinical Development & Operations

Board of Directors

President at Pirus Biological & Vaccine Consulting

Former Consultant at McKinsey & Co., Inc.

Co-Founder at CryptoMedix, Inc.

Chairman of the Board, President & Chief Executive Officer at Aptose Biosciences, Inc.

Former Chief Financial Officer & Senior Vice President at Nabisco, Inc.

Former Executive Vice President-Neuroimmunology at EMD Serono, Inc.

Co-Founder at Oncolytics Biotech Inc.

Paths to Oncolytics Biotech Inc.
Potential Connections via
Relationship Science
You
Oncolytics Biotech Inc.
Recent Transactions
Details Hidden

Oncolytics Biotech Inc. issued . USD Units Consisting of Common Stock and Warrants

Details Hidden

Oncolytics Biotech Inc. issued . USD Common Shares

Details Hidden

Oncolytics Biotech Inc. issued CAD Units Consiting of Common Stock and Warrants

Transaction Advisors
Auditor

Advised onOncolytics Biotech Inc. issued CAD Common Stock

Underwriter

Advised onOncolytics Biotech Inc. issued USD Common Stock

Underwriter

Advised onOncolytics Biotech Inc. issued CAD Units Consisting of Common Stock and Warrants

Managing Director

Advised onOncolytics Biotech Inc. issued . USD Units Consisting of Common Stock and Warrants

Professional

Advised onOncolytics Biotech Inc. issued . USD Common Shares

Managing Director

Advised onOncolytics Biotech Inc. issued . USD Units Consisting of Common Stock and Warrants

Advisors & Consultants
Legal Advisor

Partner, Co-Head of Corporate Department & Co-Head of Mergers & Acquisitions Practice at Bennett Jones LLP

Legal Advisor

Partner at Bennett Jones LLP

Legal Advisor

Partner at Bennett Jones LLP

Clients

Adlai Nortye Biopharma Co. Ltd. is a Chinese company located in Hangzhou. The firm engages in research and development in biotechnology.The company says this about itself: Adlai Nortye is a science-led biopharmaceutical company dedicated to discovering, developing and commercializing new drugs in the field of oncology/immuno-oncology. Our mission is to improve patient lives by identifying and acquiring differentiated innovative medicines that help people live better and longer. Through close collaboration with global partners, we have successfully positioned ourselves in the fields of immuno-oncology/oncology and have several programs ongoing from early pre-clinical to phase 3 ready.

Key Stats and Financials As of 2020
Market Capitalization
$244M
Total Enterprise Value
$70.2M
Earnings Per Share
$-0.43
TEVNet Income
-4.04x
Debt TEV
0x
Three Year Compounded Annual Growth Rate Of Revenue
0%
Revenue
$0
Net Profit
$-17.4M
EBITDA
$-19.3M
Total Debt
$310K
Total Equity
$19.1M
Non-Profit Donations & Grants
$10K - $25K
2016
$10K - $25K
2015
$10K - $25K
2014
Suppliers
Roche Holding AG Hospitals & Patient Services | Basel, Switzerland

Roche Holding ag Roche Personalised Healthcare – our mission The healthcare landscape is constantly changing. Patients, physicians and payers demand safer, more effective treatments, while investors search after robust and sustainable business models. Growing demand for highly effective, impactful medicines is being driven by an aging population, healthcare and economic pressures. But an influx of new technologies enables Roche to meet this need by offering innovative tests and medicines. These healthcare drivers have led us in one direction – ‘Roche Personalised Healthcare’. At Roche, ‘Personalised Healthcare’ is at the core of our business strategy

Government of Canada Holding Companies | Ottawa, Canada

The federal government of Canada is the body responsible for the federal administration of Canada. In Canadian English, the term can mean either the collective set of institutions (the legislative, executive, and judicial branches) or specifically the Queen-in-Council (the executive, also called Her Majesty's Government.

Bristol-Myers Squibb Company Medical Support Services | New York, New York

Bristol-Myers Squibb Company Our company has a strong legacy of innovation that began in New York in 1858 when Edward R. Squibb, M.D., founded a pharmaceutical company in Brooklyn, and in 1887 when two friends, William McLaren Bristol and John Ripley Myers purchased a struggling drug manufacturing firm in Clinton. Together, they laid the foundation for our company today — a global BioPharma leader that continues this legacy of innovation.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Oncolytics Biotech Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Oncolytics Biotech Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Oncolytics Biotech Inc..